{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:58:28Z","timestamp":1779231508286,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Pfizer Corporation Hong Kong Limited"},{"name":"Direct Grant for Research from the Chinese University of Hong Kong","award":["2041413"],"award-info":[{"award-number":["2041413"]}]},{"name":"Li Ka Shing Institutes for Health Sciences, The Chinese University of Hong Kong"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.bcp.2012.01.013","type":"journal-article","created":{"date-parts":[[2012,1,27]],"date-time":"2012-01-27T21:50:13Z","timestamp":1327701013000},"page":"1146-1158","source":"Crossref","is-referenced-by-count":32,"title":["Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus\/vinblastine combination in hepatocellular carcinoma"],"prefix":"10.1016","volume":"83","author":[{"given":"Qian","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian Wai Yan","family":"Lui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia Pik Yuk","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suk Hang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret Heung Ling","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen Lam","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2012.01.013_bib0005","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMsa050467","article-title":"Major causes of death among men and women in China","volume":"353","author":"He","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bcp.2012.01.013_bib0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(01)00486-7","article-title":"Global cancer statistics in the year 2000","volume":"2","author":"Parkin","year":"2001","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bcp.2012.01.013_bib0025","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1158\/1078-0432.CCR-04-0941","article-title":"mTOR and P70S6 kinase expression in primary liver neoplasms","volume":"10","author":"Sahin","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bcp.2012.01.013_bib0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12032-009-9201-4","article-title":"The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma","volume":"27","author":"Zhou","year":"2010","journal-title":"Medical Oncology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccr.2006.07.003","article-title":"Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin","volume":"10","author":"Phung","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2012.01.013_bib0040","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/ijc.21532","article-title":"In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer","volume":"118","author":"Ito","year":"2006","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.bcp.2012.01.013_bib0045","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/ijc.22442","article-title":"Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model","volume":"120","author":"Lang","year":"2007","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.bcp.2012.01.013_bib0050","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0055","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0060","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.bcp.2012.01.013_bib0065","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1002\/cncr.26165","article-title":"Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2012.01.013_bib0070","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1158\/0008-5472.CAN-06-4490","article-title":"RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer","volume":"67","author":"Mabuchi","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.bcp.2012.01.013_bib0075","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-4-25","article-title":"Overcoming cisplatin resistance by mTOR inhibitor in lung cancer","volume":"4","author":"Wu","year":"2005","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.bcp.2012.01.013_bib0080","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/sj.onc.1208479","article-title":"An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma","volume":"24","author":"Patil","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2012.01.013_bib0085","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2164-10-26","article-title":"A novel regulatory event-based gene set analysis method for exploring global functional changes in heterogeneous genomic data sets","volume":"10","author":"Tung","year":"2009","journal-title":"BMC Genomics"},{"key":"10.1016\/j.bcp.2012.01.013_bib0090","first-page":"721","article-title":"Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma","volume":"38","author":"Zhou","year":"2011","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0095","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.1605.3.12","article-title":"Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin","volume":"3","author":"VanderWeele","year":"2004","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.bcp.2012.01.013_bib0100","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.ejca.2005.12.018","article-title":"Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel","volume":"42","author":"Faried","year":"2006","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.bcp.2012.01.013_bib0105","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1124\/mol.106.032284","article-title":"Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1","volume":"71","author":"Lui","year":"2007","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0110","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.bcp.2009.10.021","article-title":"Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1","volume":"79","author":"Hong","year":"2010","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0115","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/carcin\/bgp253","article-title":"Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells","volume":"30","author":"Lui","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2012.01.013_bib0120","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/onc.2010.529","article-title":"FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation","volume":"30","author":"Lui","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2012.01.013_bib0125","first-page":"716","article-title":"Estrogen-receptor analyses \u2013 correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies","volume":"109","author":"McCarty","year":"1985","journal-title":"Archives of Pathology & Laboratory Medicine"},{"key":"10.1016\/j.bcp.2012.01.013_bib0130","first-page":"1087","article-title":"Inhibition of phosphatidylinositol 3\u2032-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models","volume":"62","author":"Hu","year":"2002","journal-title":"Cancer Research"},{"key":"10.1016\/j.bcp.2012.01.013_bib0135","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1101\/gad.973602","article-title":"p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas","volume":"16","author":"Singh","year":"2002","journal-title":"Genes & Development"},{"key":"10.1016\/j.bcp.2012.01.013_bib0140","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1097-2765(01)00323-9","article-title":"Regulation of PTEN transcription by p53","volume":"8","author":"Stambolic","year":"2001","journal-title":"Molecular Cell"},{"key":"10.1016\/j.bcp.2012.01.013_bib0145","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-3-30","article-title":"Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma","volume":"3","author":"Wang","year":"2010","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.canlet.2008.08.018","article-title":"Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma","volume":"273","author":"Tam","year":"2009","journal-title":"Cancer Letters"},{"key":"10.1016\/j.bcp.2012.01.013_bib0155","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2559.2007.02738.x","article-title":"Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma","volume":"51","author":"Chau","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0160","first-page":"25","article-title":"Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma","volume":"28","author":"Fleischer","year":"2006","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0165","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2005.09.010","article-title":"Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy","volume":"44","author":"Sieghart","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0170","first-page":"2207","article-title":"Bcl-2 positivity in B and C hepatitis and hepatocellular carcinomas","volume":"55","author":"Yildiz","year":"2008","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0175","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s12032-010-9519-y","article-title":"Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC)","volume":"28","author":"Yang","year":"2011","journal-title":"Medical Oncology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0180","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1007\/s004240100014","article-title":"Proliferative and apoptotic activity in hepatocellular carcinoma and surrounding non-neoplastic liver tissue","volume":"442","author":"Pizem","year":"2001","journal-title":"Pflugers Archiv-European Journal of Physiology"},{"key":"10.1016\/j.bcp.2012.01.013_bib0185","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-06-2757","article-title":"Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis","volume":"13","author":"Marimpietri","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bcp.2012.01.013_bib0190","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1002\/pmic.200600119","article-title":"Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line","volume":"6","author":"Campostrini","year":"2006","journal-title":"Proteomics"},{"key":"10.1016\/j.bcp.2012.01.013_bib0195","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood.V94.12.4143","article-title":"Antiangiogenesis is produced by nontoxic doses of vinblastine","volume":"94","author":"Vacca","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2012.01.013_bib0200","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.ejca.2004.02.027","article-title":"Systemic therapy for advanced hepatocellular carcinoma: a review","volume":"40","author":"Nowak","year":"2004","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.bcp.2012.01.013_bib0205","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ijc.1498","article-title":"Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma","volume":"94","author":"Nies","year":"2001","journal-title":"International Journal of Cancer"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295212000603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295212000603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T02:35:00Z","timestamp":1686710100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295212000603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0006295212000603"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2012.01.013","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}